Bioequivalence of two lamivudine tablet formulations

Arzneimittel-Forschung/Drug Research

Volumn 51, Issue 4, 2001, Pages 310-314

  Santos Magalhaes N S ^a   Pontes, A ^a   Cavalcante, R M ^a   Costa, R M R ^a   Rangel, F A ^a   Guimaraes M I V ^a   De Carvalho, J N L ^a   De Souza, S D F ^a   De Oliveira, H M ^a   Esteves, I L C ^a   Ramalho, M S ^a   Vieira, S L A ^a   Alves, A J ^a  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

CAS 134678 17 4; Lamivudine, bioequivalence studies

Indexed keywords

LAMIVUDINE;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONFORMATION; DRUG PURIFICATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MAXIMUM ALLOWABLE CONCENTRATION; TABLET FORMULATION;

EID: 0035032970     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1300043     Document Type: Article

References (19)

1. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog
2. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or midly symptomatic human immunodeficiency virus infection: A phase I/II study
3. (-)-2′-deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro
4. A phase I/II study of 2′-deoxy-3′-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection
5. The biochemical basis for the differential anti-human immunodeficiency virus activity of two enantiomers of 2′,3′-dideoxy-3′-thiacytidine
6. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in 4MDD region of reverse transcriptase
7. Lamivudine or stavudine in two and there-drug combinations against human immunodeficiency virus type 1 replication in vitro
8. The same mutation that encodes low-level human immunodeficiency virus type-1 resistance to 2′3′-dideoxyinosine and 2′3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′3′-dideoxy-3′-thiacytidine
9. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudina monotherapy
10. Combination therapy for infection due to human immunodeficiency virus type 1
11. Combination antiretroviral therapy for the treatment of human immunodefficiency virus type-1 infection
12. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel
13. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy
14. In vivo bioequivalence guidances
15. Rapid quantitation of (-)-2′-deoxy-3′-thiacytidine in human serum by high-performance liquid chromatography with ultraviolet detection
16. Bioequivalence of two thorazine tablet formulations using radio-immunoassay and gas chromatographic-mass spectrometric methods
17. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability
18. A new statistical procedure for testing equivalence in two-group comparative bioavailability trials
19. A safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: A phase I study